Mersana Therapeutics, Inc. has introduced a analysis collaboration and industrial license settlement with a subsidiary of Merck KGaA, Darmstadt, Germany to find novel Immunosynthen antibody drug conjugates (ADCs) directed towards as much as two targets.

Immunosynthen, Mersana Therapeutics’ proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that regionally activate STING signaling in each ​tumor-resident immune cells and in antigen-expressing tumor cells, unlocking the anti-tumor potential of innate immune stimulation.​ 

“Constructing on our deep experience within the ADC area, we’re centered on the invention of next-generation state-of-the-art ADC medicine,” mentioned Paul Lyne, head of analysis unit, oncology, Merck KGaA, Darmstadt, Germany. 

“An method that may straight goal the tumor microenvironment with an immunomodulatory ADC has the potential to convey the advantages of this immunotherapy to a broader group of sufferers. This collaboration with Mersana to design novel immunostimulatory ADCs that may harness the potential of the STING pathway is a perfect complement to our innovation on this space.” 

The STING pathway is a elementary technique of producing innate immune responses that may result in anti-tumor exercise and immunological reminiscence. Mersana Therapeutics has generated preclinical information demonstrating Immunosynthen’s capacity to allow extremely focused STING activation inside each tumor cells and tumor-resident myeloid cells whereas avoiding undesirable systemic results. 

Mersana Therapeutics’ growing position

“We’re happy to be partnering with Merck KGaA, Darmstadt, Germany in a collaboration designed to increase the attain of our Immunosynthen platform and produce novel new product candidates ahead with the potential to profit sufferers,” mentioned Anna Protopapas, president and chief govt officer of Mersana Therapeutics. 

“With three vital new collaborations signed in 2022 alone, we’re demonstrating Mersana’s growing position as a companion of selection throughout the ADC area.” 

Beneath the phrases of the settlement, Mersana Therapeutics will develop novel ADC product candidates towards as much as two targets using its Immunosynthen platform to conjugate proprietary antibodies from Merck KGaA, Darmstadt, Germany.

Mersana Therapeutics will likely be chargeable for sure discovery actions, in addition to restricted preclinical manufacturing and provide obligations, which will likely be reimbursed by Merck KGaA, Darmstadt, Germany. Merck KGaA, Darmstadt, Germany will likely be solely chargeable for in vitro and in vivocharacterization, different preclinical work, and all medical growth and potential commercialization actions referring to any ensuing product candidates.  

Mersana Therapeutics will obtain an upfront cost of $30 million. Mersana Therapeutics can also be eligible to obtain reimbursement of sure prices, as much as $800 million in potential regulatory, growth and industrial milestone funds, and tiered royalties as much as the low double-digit percentages on worldwide web gross sales of any authorized ADCs developed beneath the settlement.  

Source link